Last reviewed · How we verify
NBP608 (Low Potency)
NBP608 is a low-potency compound developed by SK Bioscience with an undisclosed mechanism of action currently in phase 3 clinical development.
At a glance
| Generic name | NBP608 (Low Potency) |
|---|---|
| Sponsor | SK Bioscience Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding NBP608's specific molecular mechanism. As a phase 3 asset from SK Bioscience, it represents an investigational therapeutic candidate, but detailed mechanistic data has not been widely disclosed in accessible literature or databases.
Approved indications
Common side effects
Key clinical trials
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Safety Study of NBP608 in Healthy Adult Volunteers (PHASE1)
- Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over (PHASE2, PHASE3)
- The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBP608 (Low Potency) CI brief — competitive landscape report
- NBP608 (Low Potency) updates RSS · CI watch RSS
- SK Bioscience Co., Ltd. portfolio CI